The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells

Oncotarget

Volumn 6, Issue 7, 2015, Pages 4745-4756

  Wei, Ning ^a,b   Chu, Edward ^a,b   Wu, Shao yu ^a,b   Wipf, Peter ^b,c   Schmitz, John C ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Apoptosis; Human colorectal cancer; NF B; Protein kinase D; Regorafenib

Indexed keywords

CRT 0066101; HEAT SHOCK PROTEIN 27; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE D; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; REGORAFENIB; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE C; PYRIDINE DERIVATIVE; SMALL INTERFERING RNA;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMMUNOENZYME TECHNIQUES; PHENYLUREA COMPOUNDS; PROTEIN KINASE C; PYRIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84924989810     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2938     Document Type: Article

References (34)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
2. Kohne CH and Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. The oncologist. 2009; 14(5):478-488.
3. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clinical colorectal cancer. 2012; 11(1):1-13.
4. Kerbel RS. Tumor angiogenesis. The New England journal of medicine. 2008; 358(19):2039-2049.
5. Markowitz SD and Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. The New England journal of medicine. 2009; 361(25):2449-2460.
6. Cathomas G. PIK3CA in Colorectal Cancer. Frontiers in oncology. 2014; 4:35.
7. Aoki Y, Niihori T, Narumi Y, Kure S and Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Human mutation. 2008; 29(8):992-1006.
8. Chiang AC and Massague J. Molecular basis of metastasis. The New England journal of medicine. 2008; 359(26):2814-2823.
9. Heinemann V, Douillard JY, Ducreux M and Peeters M. Targeted therapy in metastatic colorectal cancer - an example of personalised medicine in action. Cancer treatment reviews. 2013; 39(6):592-601.
10. Lievre A and Laurent-Puig P. [Biology applied to cancer treatments: the example of colorectal cancer]. La Revue du praticien. 2010; 60(8):1100-1102.
11. Strumberg D and Schultheis B. Regorafenib for cancer. Expert opinion on investigational drugs. 2012; 21(6):879-889.
12. Chen D, Wei L, Yu J and Zhang L. Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(13):3472-3484.
13. Andre T, Raymond E and de Gramont A. Regorafenib for metastatic colorectal cancer. Lancet. 2013; 381(9877):1536-1537.
14. Rozengurt E. Protein kinase D signaling: multiple biological functions in health and disease. Physiology. 2011; 26(1):23-33.
15. LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P and Wang QJ. Protein kinase D as a potential new target for cancer therapy. Bba-Rev Cancer. 2010; 1806(2):183-192.
16. Rey O, Sinnett-Smith J, Zhukova E and Rozengurt E. Regulated nucleocytoplasmic transport of protein kinase D in response to G protein-coupled receptor activation. J Biol Chem. 2001; 276(52):49228-49235.
17. Liljedahl M, Maeda Y, Colanzi A, Ayala I, Van Lint J and Malhotra V. Protein kinase D regulates the fission of cell surface destined transport carriers from the trans-Golgi network. Cell. 2001; 104(3):409-420.
18. Wei N, Chu E, Wipf P and Schmitz JC. Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer. Molecular cancer therapeutics. 2014; 13(5):1130-41.
19. LaValle CR, Bravo-Altamirano K, Giridhar K, Chen J, Sharlow ER, Lazo JS, Wipf P and Wang QJ. Novel protein kinase D inhibitors cause potent arrest in cancer cell growth and motility. Faseb J. 2010; 24.
20. Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R and Vodicka P. Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis. 2012; 27(2):211-218.
21. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews. 2006; 58(3):621-681.
22. Acunzo J, Katsogiannou M and Rocchi P. Small heat shock proteins HSP27 (HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. The international journal of biochemistry & cell biology. 2012; 44(10):1622-1631.
23. Kostenko S and Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cellular and molecular life sciences: CMLS. 2009; 66(20):3289-3307.
24. Sakamoto K and Maeda S. Targeting NF-kappaB for colorectal cancer. Expert opinion on therapeutic targets. 2010; 14(6):593-601.
25. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH and Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International journal of cancer Journal international du cancer. 2011; 129(1):245-255.
26. Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Molecular cancer therapeutics. 2010; 9(5):1136-1146.
27. Fakih M. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert review of anticancer therapy. 2013; 13(4):427-438.
28. Potente M, Gerhardt H and Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146(6):873-887.
29. Bergers G and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature reviews Cancer. 2008; 8(8):592-603.
30. Ebos JM and Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature reviews Clinical oncology. 2011; 8(4):210-221.
31. Meyerhardt JA and Mayer RJ. Systemic therapy for colorectal cancer. The New England journal of medicine. 2005; 352(5):476-487.
32. Berg M and Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discovery medicine. 2012; 14(76):207-214.
33. Vazquez A, Bond EE, Levine AJ and Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature reviews Drug discovery. 2008; 7(12):979-987.
34. Robles AI and Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harbor perspectives in biology. 2010; 2(3):a001016.